

Clinical Studies

Ciernik IF, Greiss AM. **Visualization of the tumor cavity after lumpectomy of breast cancer for postoperative radiotherapy.** Clinical and Translational Radiation Oncology. 2019 Jan; 14:47–50.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279963/>

de Blanck SR, Rydhög JS, Larsen KR, Clementsen PF, Josipovic M, Aznar MC, af Rosenschöld PM, Jølcck RI, Specht L, Andresen TL, Persson GF. **Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer.** Clinical and Translational Radiation Oncology. 2018 Nov; 13:24–8.
<https://pubmed.ncbi.nlm.nih.gov/30258990/>

de Blanck SR, Scherman-Rydhög J, Siemsen M, Christensen M, Baeksgaard L, Irming Jølcck R, Specht L, Andresen TL, Persson GF. **Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of esophageal cancer.** Br J Radiol. 2018 Dec;91(1092):20180236.
<https://pubmed.ncbi.nlm.nih.gov/29975152/>

de Ridder M, Gerbrandy LC, de Reijke TM, Hinnen KA, Hulshof MCCM. **BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial.** BJR. 2020 Jun 1;20200241.
<https://www.birpublications.org/doi/abs/10.1259/bjr.20200241>

Machiels M, Voncken FEM, Jin P, Dieren JM van, Bartels-Rutten A, Alderliesten T, Aleman BMP, Hooft JE van, Hulshof MCCM. **A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging.** Practical Radiation Oncology. 2019 Nov 1;9(6): e506–15.
<https://pubmed.ncbi.nlm.nih.gov/31279938/>

Rydhög JS, Mortensen SR, Larsen KR, Clementsen P, Jølcck RI, Josipovic M, Aznar MC, Specht L, Andresen TL, Rosenschöld PM af, Persson GF. **Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer.** Radiotherapy and Oncology. 2016 Oct;121(1):64–9.
<https://pubmed.ncbi.nlm.nih.gov/27443450/>

Rydhög Scherman J, Perrin R, Jølcck RI, Gagnon-Moisan F, Larsen KR, Clementsen P, Riisgaard de Blanck S, Fredberg Persson G, Weber DC, Lomax T, Andresen TL, Munck af Rosenschöld P. **Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer.** Radiotherapy and Oncology. 2017 Mar;122(3):393–9.
<https://pubmed.ncbi.nlm.nih.gov/28104299/>

Scherman Rydhög J, Riisgaard de Blanck S, Josipovic M, Irming Jølcck R, Larsen KR, Clementsen P, Lars Andersen T, Poulsen PR, Fredberg Persson G, Munck af Rosenschöld P. **Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer.** Radiotherapy and Oncology. 2017 Apr;123(1):78–84.
<https://www.ncbi.nlm.nih.gov/pubmed/28245908>

Non-Clinical Studies

Bertholet J, Knopf A, Eiben B, McClelland J, Grimwood A, Harris E, Menten M, Poulsen P, Nguyen DT, Keall P, Oelfke U. **Real-time intrafraction motion monitoring in external beam radiotherapy.** Phys Med Biol. 2019 Aug;64(15):15TR01.

<https://pubmed.ncbi.nlm.nih.gov/31226704/>

Brown KH, Ghita M, Schettino G, Prise KM, Butterworth KT. **Evaluation of a Novel Liquid Fiducial Marker, BioXmark®, for Small Animal Image-Guided Radiotherapy Applications.**

<https://pubmed.ncbi.nlm.nih.gov/32443537/>

Clerc-Renaud B, Boss M-K, Griffin LR, LaRue SM, Leary D. **Potential for BioXmark liquid fiducial marker to improve identification of superficial component of canine oral tumors for computer-based radiation therapy planning.** Can Vet J. 2019 Oct;60(10):1072–80.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741831/>

De Roover R, Crijns W, Poels K, Peeters R, Draulans C, Haustermans K, Depuydt T. **Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer.** Med Phys. 2018 May;45(5):2205–17.

<https://www.ncbi.nlm.nih.gov/pubmed/29537613>

Dobiasch S, Kampfer S, Burkhardt R, Schilling D, Schmid TE, Wilkens JJ, Combs SE. **BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model: Experiences with a liquid fiducial marker.** Strahlenther Onkol. 2017 Dec;193(12):1039–47.

<https://www.ncbi.nlm.nih.gov/pubmed/28808749>

Hamming VC, Brouwer CL, Van Goethem MJ, Jolck RI, Van Leijsen C, Van den Bergh ACM. **PO-0866: Visibility, image artifacts and proton dose perturbation of fiducial markers.** Radiotherapy and Oncology. 2017 May;123:S471–2.

[https://www.thegreenjournal.com/article/S0167-8140\(17\)31303-8/pdf](https://www.thegreenjournal.com/article/S0167-8140(17)31303-8/pdf)

Jelvehgaran P, Alderliesten T, Weda JJA, de Bruin M, Faber DJ, Hulshof MCCM, van Leeuwen TG, van Herk M, de Boer JF. **Visibility of fiducial markers used for image-guided radiation therapy on optical coherence tomography for registration with CT: An esophageal phantom study.** Med Phys. 2017 Dec;44(12):6570–82.

<https://www.ncbi.nlm.nih.gov/pubmed/29023771>

Mortensen SR, Scherman JB, Larsen KR, Jølcck RI, Persson GF, Hansen AE, Eriksen T, Specht L. **Use of a Novel Liquid Fiducial Marker Injected With Endoscopic Ultrasound Equipment for Use in Image Guided Radiation Therapy of Thoracic Tumors (Porcine Model).** International Journal of Radiation Oncology • Biology • Physics. 2014 Sep 1;90(1): S651.

[http://www.redjournal.org/article/S0360-3016\(14\)02577-2/abstract](http://www.redjournal.org/article/S0360-3016(14)02577-2/abstract)

Rydhög JS, Jølcck RI, Andresen TL, Rosenschöld PM af. **PO-0964: Artefact quantification of liquid and solid fiducial marker in single and dual energy CT with MAR.** Radiotherapy and Oncology. 2015 Apr 1;115: S510.

<http://nanovi.com/wp-content/uploads/2015/05/Rydhög-J-et-al.-poster.pdf>

Scherman JR, Irming Jølk R, Andresen TL, Munck af Rosenschöld P. **Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy: A new liquid fiducial marker for IGRT.** Med Phys. 2015 May 15;42(6Part1):2818–26.

<https://www.ncbi.nlm.nih.gov/pubmed/26127034>

Schneider S, Aust DE, Brückner S, Welsch T, Hampe J, Troost EGC, Hoffmann AL. **Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI.** Strahlenther Onkol. 2019 Aug;195(8):756–63.

<https://pubmed.ncbi.nlm.nih.gov/31143995/>

Schneider S, Jølk RI, Troost EGC, Hoffmann AL. **Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom.** Med Phys. 2018 Jan;45(1):37–47.

<https://www.ncbi.nlm.nih.gov/pubmed/29136287>

Troost E, Menkel S, Enghardt W, Hytry J, Kunath D, Makocki S, Hoffmann A, Jølk R. EP-1710: **Chemical stability of BioXmark® following normofractionated and single-fraction proton beam therapy.**

Radiotherapy and Oncology. 2017 May 1;123:S937–8.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6871657/>

Hafeez S, Hansen VN, McNair H, Harris E, Jones K, Schmidt M, Kumar P, Huddart R. **Assessing feasibility of a new fundicial marker (BioXmark) for bladder tumor localization and position verification during radical radiotherapy in a porcine phantom.** Abstract 30th EUS Annual Meeting, New Orleans, LA, 2015 May 16.

http://engineering-urology.org/am/30EUS_2015.pdf (Abstract 8; P: 22)